Results 171 to 180 of about 22,136 (209)
Some of the next articles are maybe not open access.
Drugs of Today, 2004
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability.
Sarah, Aronson, Pedro, Delgado
openaire +2 more sources
Escitalopram, a selective serotonin reuptake inhibitor (SSRI) was recently approved by the United States Food and Drug Administration (FDA) for the treatment of major depression. This chapter reviews preclinical and clinical studies with escitalopram, focusing on its therapeutic profile of action and tolerability.
Sarah, Aronson, Pedro, Delgado
openaire +2 more sources
Escitalopram Prevents Relapse in Older Patients With Major Depressive Disorder
American Journal of Geriatric Psychiatry, 2007 Objective: The present study investigated the efficacy and tolerability of escitalopram in the prevention of relapse of major depressive disorder (MDD) in older patients who had responded to acute treatment with escitalopram.
Philip Gorwood
exaly +2 more sources
Expert Opinion on Investigational Drugs, 2002
Escitalopram oxalate (S-citalopram, Lexapro), a selective serotonin re-uptake inhibitor antidepressant which is the S-enantiomer of citalopram, is in clinical development worldwide for the treatment of depression and anxiety disorders. Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that ...
openaire +2 more sources
Escitalopram oxalate (S-citalopram, Lexapro), a selective serotonin re-uptake inhibitor antidepressant which is the S-enantiomer of citalopram, is in clinical development worldwide for the treatment of depression and anxiety disorders. Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that ...
openaire +2 more sources